TLC-ART Pipeline

The primary objective of the TLC-ART research program revolves around the advancement of long-acting injectables for the treatment of infectious diseases and cancer. Our aim is to create formulations of either single or combined drugs that exhibit prolonged effectiveness and the ability to specifically target disease sites. The pharmaceutical platform we employ utilizes approved lipids and employs scalable, reproducible, and straightforward manufacturing processes.

TLC stands for “Targeted Long-acting”. TLC products are all based on our Drug-combination Nanoparticle technology (DcNP). DcNP enable multiple agents in single injectables.

• TLC-ART 101: lopinavir-ritonavir-tenofovir PMPA (subcutaneous)
• TLC-ART 201: lopinavir-ritonavir-tenofovir PMPA-lamivudine (subcutaneous)
• TLC-ART 301: tenofovir PMPA-lamivudine-dolutegravir (Long-acting TLD, subcutaneous)
• TLC-ART 302: tenofovir alafenamide-lamivudine-dolutagravir (subcutaneous)
• TLC-GT 101: gemcitabine-paclitaxel (intravenous, intraperitoneal, or subcutaneous)

  
TLC-ART Pipeline in details
    
HIV
 coming soon

    
HBV
 coming soon

    
Cancer
 coming soon

   

Publications

Last Update: June 21, 2023